Vivani's semaglutide implant faces its first human PK test by year-end
SLIM-1 will compare a subdermal semaglutide implant against injected semaglutide in 20 obesity patients, testing whether the delivery format works before any Phase 2 dosing decision.
Executive Summary
- Vivani Medical is running the first human test of a subdermal implant designed to deliver semaglutide continuously rather than through weekly injections, with results expected before year-end.
- The trial is built as a head-to-head pharmacokinetic comparison against injected semaglutide, so the readout will show directly whether the implant can reproduce the drug's known exposure profile rather than establish a new efficacy signal.
- A workable pharmacokinetic match would open the door to a higher-dose implant configuration and a Phase 2 study; a mismatch would call the delivery approach into question before any weight-loss data could be generated.
- The obesity GLP-1 field is dense with late-stage oral and injectable entrants, so the implant's relevance rests entirely on solving an adherence problem the injectable class already addresses with efficacy, not on offering a new mechanism.
The trial
SLIM-1 (NCT07430059) is a Phase 1 study evaluating a low-dose configuration of NPM-139, Vivani's subcutaneous semaglutide implant, in adults with a body mass index between 27 and 40 kg/m2. The trial is randomized against an active comparator arm of injected semaglutide, and its four primary endpoints cover adverse events, area under the plasma concentration-time curve, maximum plasma concentration, and time to maximum concentration. The design targets pharmacokinetic bridging, not a weight-loss efficacy claim: the question is whether an implant can reproduce the exposure profile of an already-approved injectable rather than beat it. NCT07430059Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide ImplantNCT07430059
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Where it stands
The trial is registered as Not yet recruiting, with a start date of April 2026 and a primary completion date of August 1, 2026. It targets 20 patients and will run in Australia through a contract research collaborator. Vivani's Chief Executive Officer, Adam Mendelsohn, said the company anticipates topline SLIM-1 results by the end of 2026, based on the pace of execution on its earlier LIBERATE-1 implant trial in 2025. The registry shows no protocol amendments since the trial's initial registration in February 2026, and the enrollment target has not changed from its original 20-patient plan. NCT07430059+1Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide ImplantNCT07430059Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 13, 2026
What comes next
Vivani has also disclosed work on a next-generation NPM-139 configuration designed to carry semaglutide doses in line with Wegovy dosing, and it plans a pre-IND meeting with the FDA and an IND filing to support a Phase 2 dose-ranging study in 2027, contingent on SLIM-1 results. That sequencing means SLIM-1's pharmacokinetic data, not a weight-loss outcome, is the near-term gate: a match to semaglutide's known exposure profile would support moving to the higher-dose implant and a larger study, while a mismatch would require reworking the delivery platform before any efficacy testing could begin. VivaniVivani Medical Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 13, 2026
The competitive field
GLP-1 receptor agonists for obesity are one of the most active areas in clinical development, with multiple sponsors running Phase 3 or Phase 4 programs sharing the same GLP-1 receptor target and mechanism class. None of these direct comparators use a subdermal implant; Vivani's differentiation rests on solving the adherence problem inherent to weekly or daily dosing across an already-validated drug class, not on a new mechanism. Against a field where the injectable and oral formulations already established efficacy, the bar SLIM-1 must clear is a pharmacokinetic profile close enough to injected semaglutide to justify carrying an already-proven drug into a new delivery format.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.